OXiGENE Announces $5 Million Private Placement
April 11, 2013 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 11, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it...
OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents
March 20, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
OXiGENE Reports Full Year 2012 Financial Results
March 12, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 12, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported...
OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast
March 04, 2013 14:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report...
OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues to be Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Ovarian Cancer Trial
February 06, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
OXiGENE Announces Presentation at BIO CEO Conference on February 12th
February 04, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 4, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors
January 23, 2013 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Regains Nasdaq Closing Bid Price Compliance
January 16, 2013 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced...
OXiGENE Announces Presentation of Encouraging OXi4503 Preclinical and Clinical Data in Acute Myelogenous Leukemia at American Society of Hematology Meeting
December 10, 2012 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
OXiGENE Announces OXi4503 Granted Orphan Designation for Treatment of Acute Myelogenous Leukemia
November 21, 2012 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that its...